Thank you to Elizabeth Hart for the excerpt from her site "Over-Vaccination: Challenging Big Pharma's lucrative over-vaccination of people and animals. We invite you to bookmark the site.
Re my previous post about my letter to Professor Peter Gøtzsche, challenging a systematic review prepared by members of the Cochrane Vaccines Field, i.e. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.
Professor Gøtzsche has responded to my letter, encouraging me to “submit a criticism” on this important matter.
I have forwarded a follow-up letter in this regard, which includes reference to my previous correspondence with Dr Tom Jefferson, and also draws parallels between human and animal vaccination, please see below:
17 July 2014
RE: Vaccine safety and aluminium adjuvants
Thank you for your response to my letter dated 8 July 2014 which challenges a systematic review prepared by the Cochrane Vaccines Field i.e. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.
In your response you encourage me to “submit a criticism” on this important matter to The Cochrane Collaboration.
As noted in my previous letter, the systematic review in question was prepared by members of the Cochrane Vaccines Field, i.e. Tom Jefferson, Melanie Rudin and Carlo Di Pietrantonj, and was published in The Lancet Infectious Diseases in 2004 (behind the paywall). The review is listed in the bibliography on the Cochrane Vaccines Field website, but is not accessible online on The Cochrane Collaboration website, so I am unable to make an online comment.
Professor Gøtzsche, as you have encouraged me to make a submission, can you please clarify how I should do this?
For your information, I originally contacted Dr Jefferson directly about this matter in March 2013. (I had previously contacted Dr Jefferson on other vaccine-related matters. He is also formally copied on my submissions re controversial ‘gain-of-function’ research in the influenza industry, see my letter to the NSABB Jan 2012 and my submission to the US CDC/HHS Dec 2012.)
Please see below the contents of my email forwarded to Dr Jefferson on 24 March 2013 in regards to his systematic review of adverse events after immunisation with aluminium-containing DTP vaccines. (Given my previous correspondence with Dr Jefferson, the tone is informal. I have added some references in the endnotes):
I’m reading your review: “Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence” (The Lancet Infectious Diseases. Vol. 4 2004.)
The summary of your review concludes: “Despite a lack of good-quality evidence we do not recommend that any further research on this topic is undertaken.” (My emphasis.)
Your review notes: “The results of our review should be interpreted within the limited quantity and quality of available evidence. Within these limits, we found no evidence that aluminium salts cause any serious or long-lasting adverse events…”
So, you admit the quantity and quality of the evidence in your review was limited, but you still say that “we do not recommend that any further research on this topic is undertaken“.
Why would you say that?